全球心绞痛药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

全球心绞痛药物市场需求预计将从 2023 年的 116.9 亿美元达到 2032 年近 162.5 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 3.73%。

心绞痛药物是用于缓解和控制与心绞痛相关的胸痛的药物，心绞痛是一种由心肌血流量减少引起的疾病。这些药物的常见类别包括硝酸盐（例如，硝酸甘油）、β-受体阻断剂（例如，美托洛尔）、钙通道阻断剂（例如，氨氯地平）和抗血小板药物（例如，阿斯匹灵).这些药物的作用是扩张血管、降低心臟工作负荷和防止血栓，进而改善心臟的氧气输送。使用这些药物有效治疗心绞痛有助于降低心绞痛发作的频率和严重程度，提高生活质量，并预防心臟病等併发症。

市场动态

心血管疾病盛行率的激增导致心绞痛的发生率更高，因此对有效的心绞痛药物的需求更大。药物研究的进步导致了新的和改进的心绞痛药物的开发，这些药物具有更好的疗效和安全性，使它们对患者和医疗保健提供者更具吸引力。此外，全球人口老化，更容易罹患心血管疾病，显着增加了对这些药物的需求。患者和医疗保健提供者对心绞痛早期诊断和治疗重要性的认识不断增强，进一步推动了市场成长。此外，旨在降低心血管疾病负担的支持性政府措施和医疗保健政策在市场成长中发挥着不可或缺的作用。医疗保健支出的增加和医疗保健基础设施的扩大，特别是在新兴经济体，提高了心绞痛药物的可近性和可用性。此外，越来越多地采用生活方式改变和预防措施来管理和降低心血管疾病的风险，也增加了对这些药物的需求。然而，高成本和潜在的副作用可能会挑战未来几年的市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球心绞痛药物市场的各个细分市场进行了包容性评估。心绞痛药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

心绞痛药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按治疗类别

• β受体阻断剂
• 钙拮抗剂
• 抗凝血剂
• 抗血小板
• 其他（硝酸盐、抗心绞痛药（雷诺嗪）、ACE 抑制剂）'

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲心绞痛药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。心绞痛药物市场的主要参与者包括安进公司、赛诺菲公司、吉利德科学公司、阿斯特捷利康公司、葛兰素史克公司、礼来公司、辉瑞公司、诺华公司、XyloCor Therapeutics Inc.、天士力製药公司本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来能力、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：心绞痛药物 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按治疗类别分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球心绞痛药物市场分析：依治疗类别

• 按治疗类别概述
• 按治疗类别进行历史和预测数据分析
• β受体阻断剂
• 钙拮抗剂
• 抗凝血剂
• 抗血小板
• 其他（硝酸盐、抗心绞痛药（雷诺嗪）、ACE 抑制剂）'

第 6 章：全球心绞痛药物市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区按国家销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲按国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 7 章：心绞痛药厂的竞争格局

• 心绞痛药物市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 8 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Amgen Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Sanofi SA
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Gilead Sciences Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• AstraZeneca Plc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• GlaxoSmithKline Plc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Eli Lilly And Company
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Novartis AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• XyloCor Therapeutics Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Tasly Pharmaceuticals Inc
• 公司简介
• 公司收入
• 产品
• 最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

The global demand for Angina Pectoris Drugs Market is presumed to reach the market size of nearly USD 16.25 Billion by 2032 from USD 11.69 Billion in 2023 with a CAGR of 3.73% under the study period 2024-2032.

Angina pectoris drugs are medications used to relieve and manage the chest pain associated with angina, a disorder caused by reduced blood flow to the heart muscle. Common classes of these drugs include nitrates (e.g., nitroglycerin), beta-blockers (e.g., metoprolol), calcium channel blockers (e.g., amlodipine), and antiplatelet agents (e.g., aspirin). These medications work by dilating blood vessels, lowering heart workload, and preventing blood clots, thereby improving oxygen delivery to the heart. Effective management of angina pectoris with these drugs helps lower the frequency and severity of angina attacks, improve quality of life, and prevent complications such as heart attacks.

MARKET DYNAMICS

The proliferating prevalence of cardiovascular diseases leads to a higher incidence of angina pectoris and, consequently, a greater demand for effective angina pectoris drugs. Advances in pharmaceutical research have resulted in the development of new and improved angina pectoris drugs that offer better efficacy and safety profiles, making them more appealing to patients & healthcare providers. Additionally, the aging global population, which is more prone to cardiovascular conditions, significantly boosts the demand for these medications. The growing awareness about the significance of early diagnosis and management of angina pectoris among patients and healthcare providers further drives market growth. Moreover, supportive government initiatives & healthcare policies aimed at lowering the burden of cardiovascular diseases play an integral role in market growth. Increased healthcare expenditure and expanding healthcare infrastructure, particularly in emerging economies, enhance the accessibility and availability of angina pectoris drugs. Furthermore, the rising adoption of lifestyle changes & preventive measures to manage and lower the risk of cardiovascular diseases also contributes to the demand for these drugs. However, high costs and potential side effects may challenge market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Angina Pectoris Drugs. The growth and trends of Angina Pectoris Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Angina Pectoris Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapeutic Class

• Beta Blockers
• Calcium Antagonists
• Anticoagulants
• Anti-Platelets
• Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)'

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Angina Pectoris Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Angina Pectoris Drugs market include Amgen Inc., Sanofi S.A., Gilead Sciences Inc., AstraZeneca Plc., GlaxoSmithKline Plc., Eli Lilly And Company, Pfizer Inc., Novartis AG, XyloCor Therapeutics Inc., Tasly Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ANGINA PECTORIS DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutic Class
  • 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANGINA PECTORIS DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS

• 5.1. Overview By Therapeutic Class
• 5.2. Historical and Forecast Data Analysis By Therapeutic Class
• 5.3. Beta Blockers Historic and Forecast Sales By Regions
• 5.4. Calcium Antagonists Historic and Forecast Sales By Regions
• 5.5. Anticoagulants Historic and Forecast Sales By Regions
• 5.6. Anti-Platelets Historic and Forecast Sales By Regions
• 5.7. Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)' Historic and Forecast Sales By Regions

6. GLOBAL ANGINA PECTORIS DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 6.1. Regional Outlook
• 6.2. Introduction
• 6.3. North America Sales Analysis
  • 6.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.3.2 North America By Segment Sales Analysis
  • 6.3.3 North America By Country Sales Analysis
  • 6.3.4 United States Sales Analysis
  • 6.3.5 Canada Sales Analysis
  • 6.3.6 Mexico Sales Analysis
• 6.4. Europe Sales Analysis
  • 6.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.4.2 Europe By Segment Sales Analysis
  • 6.4.3 Europe By Country Sales Analysis
  • 6.4.4 United Kingdom Sales Analysis
  • 6.4.5 France Sales Analysis
  • 6.4.6 Germany Sales Analysis
  • 6.4.7 Italy Sales Analysis
  • 6.4.8 Russia Sales Analysis
  • 6.4.9 Rest Of Europe Sales Analysis
• 6.5. Asia Pacific Sales Analysis
  • 6.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.5.2 Asia Pacific By Segment Sales Analysis
  • 6.5.3 Asia Pacific By Country Sales Analysis
  • 6.5.4 China Sales Analysis
  • 6.5.5 India Sales Analysis
  • 6.5.6 Japan Sales Analysis
  • 6.5.7 South Korea Sales Analysis
  • 6.5.8 Australia Sales Analysis
  • 6.5.9 South East Asia Sales Analysis
  • 6.5.10 Rest Of Asia Pacific Sales Analysis
• 6.6. Latin America Sales Analysis
  • 6.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.6.2 Latin America By Segment Sales Analysis
  • 6.6.3 Latin America By Country Sales Analysis
  • 6.6.4 Brazil Sales Analysis
  • 6.6.5 Argentina Sales Analysis
  • 6.6.6 Peru Sales Analysis
  • 6.6.7 Chile Sales Analysis
  • 6.6.8 Rest of Latin America Sales Analysis
• 6.7. Middle East & Africa Sales Analysis
  • 6.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.7.2 Middle East & Africa By Segment Sales Analysis
  • 6.7.3 Middle East & Africa By Country Sales Analysis
  • 6.7.4 Saudi Arabia Sales Analysis
  • 6.7.5 UAE Sales Analysis
  • 6.7.6 Israel Sales Analysis
  • 6.7.7 South Africa Sales Analysis
  • 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE ANGINA PECTORIS DRUGS COMPANIES

• 7.1. Angina Pectoris Drugs Market Competition
• 7.2. Partnership/Collaboration/Agreement
• 7.3. Merger And Acquisitions
• 7.4. New Product Launch
• 7.5. Other Developments

8. COMPANY PROFILES OF ANGINA PECTORIS DRUGS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Market Concentration Rate
• 8.3. Amgen Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Company Revenue
  • 8.3.3 Products
  • 8.3.4 Recent Developments
• 8.4. Sanofi S.A.
  • 8.4.1 Company Overview
  • 8.4.2 Company Revenue
  • 8.4.3 Products
  • 8.4.4 Recent Developments
• 8.5. Gilead Sciences Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Company Revenue
  • 8.5.3 Products
  • 8.5.4 Recent Developments
• 8.6. AstraZeneca Plc.
  • 8.6.1 Company Overview
  • 8.6.2 Company Revenue
  • 8.6.3 Products
  • 8.6.4 Recent Developments
• 8.7. GlaxoSmithKline Plc.
  • 8.7.1 Company Overview
  • 8.7.2 Company Revenue
  • 8.7.3 Products
  • 8.7.4 Recent Developments
• 8.8. Eli Lilly And Company
  • 8.8.1 Company Overview
  • 8.8.2 Company Revenue
  • 8.8.3 Products
  • 8.8.4 Recent Developments
• 8.9. Pfizer Inc.
  • 8.9.1 Company Overview
  • 8.9.2 Company Revenue
  • 8.9.3 Products
  • 8.9.4 Recent Developments
• 8.10. Novartis AG
  • 8.10.1 Company Overview
  • 8.10.2 Company Revenue
  • 8.10.3 Products
  • 8.10.4 Recent Developments
• 8.11. XyloCor Therapeutics Inc.
  • 8.11.1 Company Overview
  • 8.11.2 Company Revenue
  • 8.11.3 Products
  • 8.11.4 Recent Developments
• 8.12. Tasly Pharmaceuticals Inc
  • 8.12.1 Company Overview
  • 8.12.2 Company Revenue
  • 8.12.3 Products
  • 8.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Therapeutic Class (USD MN)
• Beta Blockers Market Sales By Geography (USD MN)
• Calcium Antagonists Market Sales By Geography (USD MN)
• Anticoagulants Market Sales By Geography (USD MN)
• Anti-Platelets Market Sales By Geography (USD MN)
• Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)' Market Sales By Geography (USD MN)
• Global Angina Pectoris Drugs Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Angina Pectoris Drugs Report
• Market Research Process
• Market Research Methodology
• Global Angina Pectoris Drugs Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Therapeutic Class
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Therapeutic Class (USD MN)
• Beta Blockers Market Sales By Geography (USD MN)
• Calcium Antagonists Market Sales By Geography (USD MN)
• Anticoagulants Market Sales By Geography (USD MN)
• Anti-Platelets Market Sales By Geography (USD MN)
• Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)' Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.